Disrupting the Psychedelics Sector with Ground-breaking First-to-Market and Industry-changing Innovations!

(CSE: COOL, OTC: CLABF, Frankfurt: LD6, WKN: A3CSSU)

Disrupting the Psychedelics Sector with Ground-breaking First-to-Market and Industry-changing Innovations!

(CSE: COOL, OTC: CLABF, Frankfurt: LD6, WKN: A3CSSU)

We Are An Industry Leader In The Rapidly Growing Psychedelics Market Space

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of API grade biosynthetic psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery system technology.

The Psychedelics Market Is on a Trajectory to Surpass $10BILLION!

 The market in psychedelic healthcare is on a trajectory to surpass $10 BILLION by 2027, growing from USD 4.75 Billion in 2020: representing a Compound Annual Growth Rate of 12.36%.[i]

Mental health disorders are on the rise in every country of the world and costs to the global economy could reach $16 trillion by 2030 (The Lancet Commission on global mental health and sustainable development, 2018)

Research and Markets Report: Psychedelic Drugs Market, By Drugs (LSD, Ecstasy, Phencyclidine, GHB, Ketamine, Ayahuasca, Psilocybin), Route of Administration (Oral, Injectable, Inhalation), Distribution Channel, End-Users, Application and Geography – Global Forecast to 2026
While this industry is still in its early stages, the promising potential of psychedelic medicines and pharmaceutical grade products is attracting savvy investors eager to capitalize on the emerging investment opportunities psychedelic stocks present.

THE POTENTIAL OF PSYCHEDELICS FAR EXCEEDS THE POTENTIAL OF CANNABIS,” stated Kevin O’Leary, Shark Tank co-host and chairman of O’Shares ETFs (CNBC’s Healthy Returns Summit in May ’21)









Why Psychedelics?

  • Mental health conditions and neurological disorders are on the rise with limited effective and sustaining treatments.
  • Research amassing that suggest psychedelics, such as psilocybin, offer promising and low harm profile solutions for treating depression, addiction and other mental health disorders.
  • Shift in public sentiment supporting the push for alternative approaches.
  • Quickly advancing industry with increasing attention and capital in-flows from both retail and institutional investors.
  • Paradigm shift amongst legislators and politicians in general – moving towards decriminalization and legalization for use of psychedelics for both recreational use and clinical and medicinal purposes.


The Canadian government is changing the way patients can be treated by allowing access to psychedelic therapies and restricted drugs, such as psilocybin and MDMA through the Special Access Program (SAP). The SAP program puts forth a new legal pathway to gain access to psychedelics, allowing manufacturers to sell and doctors to have access to drugs that cannot otherwise be sold or distributed in Canada. The drugs considered could be pharmaceutical, biologic or radio-pharmaceutical in nature.

Health Canada’s special access programs: Overview – Canada.ca

Core One’s Research and Medical Clinics Can Help Facilitate Patient Access

Why Core One?

  • We are the First to Market with Biosynthetic Psilocybin, with patent pending production technology
  • Potential to replace current cost-prohibitive and timely production methods with our psychedelic compounds at a fraction of market cost
  • Additional Psychedelics in Production Pipeline
  • Renowned Scientific Leadership Team

Our Renowned Scientific team!

Dr. Robert Hancock

Executive Chairman

Dr. Hancock is a leading microbiologist in Canada and has researched and taught at the University of British Columbia for nearly 40 years. Dr. Hancock OC, OBC, FRSC, a Canada Research Chair holder in Health and Genomics, a Director of the Centre for Microbial Diseases and Immunity Research and a holder of the Order of Canada for his contributions in these and other fields.

Dr. Santiago Ferro

Chief Medical Officer

Dr. Ferro is a world-renowned physician with over 20 years’ experience in pharmaceuticals, biologicals and biotech industries. Throughout his career, Dr. Ferro has held many prestigious senior research and development management positions with global responsibilities for clinical development programs, design, implementation, and analysis of clinical trials data, and has a proven record of generating and building relationships, managing projects from concept to completion, as well as designing clinical plans to meet market targets and bringing products to success.

Dr. Jan Burian

Chief Scientist

Dr. Burian is a successful biochemist and molecular biologist with extensive knowledge in operations, scale-up of fermentative API production, research and development. He has numerous academic publications to his name. He previously held a site directorship with Pfizer.

Core One Labs Listings

What markets are Core One Shares available?
Canada (CSE:COOL)
Frankfurt: LD6, WKN: A3CSSU

Peter Thiel, PayPal co-founder, and FACEBOOK’S VERY FIRST INVESTOR, INVESTS OVER US$11.9 MILLION IN A PSYCHEDELICS start up company in 2020.